Literature DB >> 16782709

Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.

Daniel L Baker1, Yuko Fujiwara, Kathryn R Pigg, Ryoko Tsukahara, Susumu Kobayashi, Hiromu Murofushi, Ayako Uchiyama, Kimiko Murakami-Murofushi, Eunjin Koh, Russell W Bandle, Hoe-Sup Byun, Robert Bittman, Dominic Fan, Mandi Murph, Gordon B Mills, Gabor Tigyi.   

Abstract

Autotaxin (ATX, nucleotide pyrophosphate/phosphodiesterase-2) is an autocrine motility factor initially characterized from A2058 melanoma cell-conditioned medium. ATX is known to contribute to cancer cell survival, growth, and invasion. Recently ATX was shown to be responsible for the lysophospholipase D activity that generates lysophosphatidic acid (LPA). Production of LPA is sufficient to explain the effects of ATX on tumor cells. Cyclic phosphatidic acid (cPA) is a naturally occurring analog of LPA in which the sn-2 hydroxy group forms a 5-membered ring with the sn-3 phosphate. Cellular responses to cPA generally oppose those of LPA despite activation of apparently overlapping receptor populations, suggesting that cPA also activates cellular targets distinct from LPA receptors. cPA has previously been shown to inhibit tumor cell invasion in vitro and cancer cell metastasis in vivo. However, the mechanism governing this effect remains unresolved. Here we show that 3-carba analogs of cPA lack significant agonist activity at LPA receptors yet are potent inhibitors of ATX activity, LPA production, and A2058 melanoma cell invasion in vitro and B16F10 melanoma cell metastasis in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782709      PMCID: PMC3505596          DOI: 10.1074/jbc.M512486200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Physiological responses to lysophosphatidic acid and related glycero-phospholipids.

Authors:  G Tigyi
Journal:  Prostaglandins Other Lipid Mediat       Date:  2001-04       Impact factor: 3.072

2.  Lysophosphatidic acids produced by lysophospholipase D in mammalian serum and body fluid.

Authors:  A Tokumura; S Yamano; T Aono; K Fukuzawa
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

Review 3.  Lysophosphatidic acid receptors.

Authors:  J J Contos; I Ishii; J Chun
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

4.  Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor.

Authors:  S W Nam; T Clair; Y S Kim; A McMarlin; E Schiffmann; L A Liotta; M L Stracke
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

5.  Expression of autotaxin mRNA in human hepatocellular carcinoma.

Authors:  G Zhang; Z Zhao; S Xu; L Ni; X Wang
Journal:  Chin Med J (Engl)       Date:  1999-04       Impact factor: 2.628

6.  Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors.

Authors:  D J Fischer; N Nusser; T Virag; K Yokoyama; D L Baker; D Bautista; A L Parrill; G Tigyi
Journal:  Mol Pharmacol       Date:  2001-10       Impact factor: 4.436

7.  Increased formation of lysophosphatidic acids by lysophospholipase D in serum of hypercholesterolemic rabbits.

Authors:  Akira Tokumura; Yumi Kanaya; Masaki Kitahara; Maki Miyake; Yasuko Yoshioka; Kenji Fukuzawa
Journal:  J Lipid Res       Date:  2002-02       Impact factor: 5.922

Review 8.  Genetic basis of human breast cancer metastasis.

Authors:  M T Debies; D R Welch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

9.  Characterization of plasma unsaturated lysophosphatidylcholines in human and rat.

Authors:  M Croset; N Brossard; A Polette; M Lagarde
Journal:  Biochem J       Date:  2000-01-01       Impact factor: 3.857

10.  Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization.

Authors:  M J Stassar; G Devitt; M Brosius; L Rinnab; J Prang; T Schradin; J Simon; S Petersen; A Kopp-Schneider; M Zöller
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

View more
  58 in total

1.  Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

Authors:  Tugan Bese; Merve Barbaros; Elif Baykara; Onur Guralp; Salih Cengiz; Fuat Demirkiran; Cevdet Sanioglu; Macit Arvas
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Ligand-based autotaxin pharmacophore models reflect structure-based docking results.

Authors:  Catrina D Mize; Ashley M Abbott; Samantha B Gacasan; Abby L Parrill; Daniel L Baker
Journal:  J Mol Graph Model       Date:  2011-09-18       Impact factor: 2.518

Review 3.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 4.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

5.  Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.

Authors:  Peng Cui; Jose L Tomsig; William F McCalmont; Sangderk Lee; Christopher J Becker; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

6.  Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.

Authors:  Sudeepti S Kuppa; Wei Jia; Shuying Liu; Ha Nguyen; Susan S Smyth; Gordon B Mills; Kevin K Dobbin; William J Hardman; Mandi M Murph
Journal:  Cancer Lett       Date:  2018-05-31       Impact factor: 8.679

7.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.

Authors:  Xiaoyu Xu; Glenn D Prestwich
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

Review 8.  Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.

Authors:  Glenn D Prestwich; Joanna Gajewiak; Honglu Zhang; Xiaoyu Xu; Guanghui Yang; Monica Serban
Journal:  Biochim Biophys Acta       Date:  2008-04-08

9.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

Authors:  Lauren P Saunders; Amy Ouellette; Russ Bandle; William Chozen Chang; Hongwen Zhou; Raj N Misra; Enrique M De La Cruz; Demetrios T Braddock
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.

Authors:  Molly K Altman; Vashisht Gopal; Wei Jia; Shuangxing Yu; Hassan Hall; Gordon B Mills; A Cary McGinnis; Michael G Bartlett; Guowei Jiang; Damian Madan; Glenn D Prestwich; Yong Xu; Michael A Davies; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-06-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.